RESEARCH ARTICLE

In vitro evaluation of antidiabetic activity of aqueous and ethanolic leaves extracts of *Chloroxylon swietenia*

Ramana Murty Kadali SLDV¹, Mangala Charan Das², Rajagopalan Vijayaraghavan¹, Ittagi Shanmukha³

¹Department of Research, Saveetha University, Chennai, Tamil Nadu, India, ²Department of Pharmacology, NRI Medical College, Chinakakani, Andhra Pradesh, India, ³Department of Pharmacology, SCS Pharmacy College, Harapanahalli, Karnataka, India

Correspondence to: Ramana Murty Kadali SLDV, E-mail: murtypharma@gmail.com

Received: December 18, 2016; Accepted: January 04, 2017

ABSTRACT

Background: *Chloroxylon swietenia* belongs to family Rutaceae. Common name - satin wood, Telugu name - billedu, bildu chettu, billu, Tamil name - vaaimaram or porasu. *C. swietenia* has been reported to have anti-inflammatory activity, antimicrobial activity, anthelmintic activity, analgesic activity, antioxidant activity, and mosquitocidal activity. **Aims and Objective:** To evaluate *in vitro* antidiabetic activity of aqueous and ethanolic leaves extracts of *C. swietenia* by α -amylase and α -glucosidase enzyme inhibitory assay. **Materials and Methods:** About 100, 200, 300, 400, 500 µg concentrations of acarbose, aqueous, and ethanolic leaves extracts of *C. swietenia* were used for the study. The absorbance values were taken in spectrophotometer at 540 nm and 546 nm for α -amylase and α -glucosidase enzyme in dose-dependent manner. Ethanolic extract exhibited more inhibitory activity when compared with aqueous extract. **Conclusion:** Results shows considerable α -amylase inhibitory activity as well as α -glucosidase inhibitory activity. The present findings indicate that aqueous and ethanolic leaves extracts of *C. swietenia* have *in vitro* antidiabetic activity.

KEY WORDS: *In Vitro* Antidiabetic Activity; *Chloroxylon swietenia*; α-glucosidase; α-amylase; Acarbose

INTRODUCTION

Advancing technology and drastic life style changes have been associated with rise in various noncommunicable disorders, including diabetes.^[1] Diabetes mellitus is a metabolic disorder characterized by impaired glucose homeostasis with disturbances of carbohydrate, fat, and protein metabolism resulting from defects in insulin secretion, insulin action or both.^[2]

Access this article online					
Website: www.njppp.com	Quick Response code				
DOI: 10.5455/njppp.2017.7.1235104012017	国際国際				

Diabetes has been on rise world over, but a major health problem and social burden in developing countries like India.^[3] Diabetes has been known in India for centuries as "a disease of rich man" but now spread among all masses. Globally, 387 million people are diabetic in 2014. India accounts for 66.84 million diabetics and stands second to China which accounts for 96.28 million.^[4] Because of this large number of diabetics, India is to be known as diabetic capital of the world.^[5,6] It is projected to be the 7th leading cause of death by 2030.^[7]

In countries like India, it is useful to employ a number of indigenous plant medicines due to the relatively high cost of allopathic medicines.^[8] There is a growing interest in herbal remedies because of their effectiveness, minimal side effects in clinical experience, and relatively low cost. Herbal drugs or their extracts are prescribed widely, even

National Journal of Physiology, Pharmacy and Pharmacology Online 2017. © 2017 Ramana Murty Kadali SLDV et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creative commons.org/licenses/by/4.0/), allowing third partiesto copy and redistribute the materialin any medium or for mat and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.

when their biological active compounds are unknown. Even the World Health Organization approves the use of plant drugs for different diseases including diabetes mellitus.^[9] Plants are good source of drugs and majority of drugs are derived directly or indirectly from them. The ethnobotanical information reported about 800 plants may possess antidiabetic potentials.^[10]

For evaluation of antidiabetic activity of drugs, *in vitro* tests can be used as initial screening tools, where the screening of large number of potential therapeutic candidates may be carried out. They might provide useful information on the mechanism of action of therapeutic agents.^[11]

An ethnobotanical survey was conducted on the medicinal plants frequently used for the management of diabetes mellitus in Warangal district, Andhra Pradesh by traditional healers. Chloroxylon swietenia,^[12,13] Costus speciosus, Tinospora cordifolia, etc., were repeatedly mentioned by the traditional healers as the mostly used for the management of diabetes millitus in the study area. Costus speciosus, T. cordifolia has been reported to have antidiabetic activity. C. swietenia belongs to family Rutaceae. Common name - satin wood, Telugu name - billedu, bildu chettu, billu, Tamil name - vaaimaram or porasu. C. swietenia has been reported to have anti-inflammatory activity.^[14] antimicrobial activity,^[15,16] anthelmintic activity,^[15,16] analgesic activity,^[17] antioxidant activity,^[17] and mosquitocidal activity.^[17] However, no previous reports are available on in vitro antidiabetic activity of this plant. Based on the claims and available evidence, it was thought worthwhile to investigate C. swietenia for diabetes.

MATERIALS AND METHODS

Plant Material and Extract Preparation

The fresh leaves of *C. swietenia* were collected locally and authenticated by Dr. Shiva kumari, Department of Botany, Andhra Loyola College. Fresh leaves of *C. swietenia* were collected and washed without squeezing to remove debris and dust particles. After shade dried (Temp $<40^{\circ}$ C)., plant material was grounded into a moderately coarse powder. Aqueous extract was prepared by maceration and ethanolic extract was prepared using soxhlet apparatus. The extract was allowed to dry. The dried extract was weighed. The % yield of each plant extract was calculated. The % of yield obtained was 8.96 and 9.16% for alcoholic and aqueous extracts, respectively. The extract was preserved in refrigerator till further use.

Inhibition of α-amylase Enzyme^[18,19]

 α -amylase (0.5 mg/ml) was mixed with the sample at various concentrations (100-500 µg/ml) to which 1% of starch solution and 100 µl of 0.2 mm of phosphate buffer

(pH -6.9) were added. The reaction was allowed to be carried out at 37°C for 5 min and terminated by addition of 2 ml of 3, 5-dinitrosalicylic acid reagent. The reaction mixture was heated for 15 min at 100°C and diluted with 10 ml of distilled water in an ice bath. α -amylase activity was determined by measuring color intensity at 540 nm in spectrophotometer.

Inhibition of α-glucosidases Enzyme^[20]

The inhibitory activity was determined by incubating 1 ml of starch solution (2% w/v maltose) with 0.2 M tris buffer (pH 8) and various concentration of sample (100-500 mg/ml). The reaction mixture was incubated at 37°C for 10 min. The reaction was initiated by adding 1 ml of α -glucosidase enzyme (1 U/ml) to it and incubation at 35°C for 40 min. Then the reaction was terminated by the addition of 2 ml of 6 N HCl. The intensity of the color was measured at 540 nm in spectrophotometer.

The results were expressed as % inhibition using the formula:

% inhibitory activity = $(Ac-As)/Ac \times 100$

Where, Ac is the absorbance of the control and As is the absorbance of the sample.

The inhibitory concentration (IC₅₀) value is defined as the concentration of inhibitor to inhibit 50% of its activity under the assayed conditions. The IC₅₀ values were determined from plots of % inhibition versus log inhibitor concentration and calculated by logarithmic regression analysis from the mean inhibitory values.

Statistical Analysis

All determinations were done in triplicate and values are expressed as the mean \pm standard error of the mean. The result is also expressed as IC₅₀ value. IC₅₀ value was calculated using regression analysis.

RESULTS

α-amylase Inhibitory Activity and α-glucosidase Inhibitory Activity

Aqueous extract of 100, 200, 300, 400, 500 μ g doses inhibits the α -amylase enzyme by 9.88%, 16.20%, 22.78%, 48.80%, and 58.51%, respectively.

Ethanolic extract of 100, 200, 300, 400, 500 μ g doses inhibits the α -amylase enzyme by 32.44%, 48.64%, 59.89%, 68.62%, and 77.90%, respectively.

Acarbose of 100, 200, 300, 400, 500 μ g doses inhibits the α -amylase enzyme by 50.91%, 61.31%, 68.23%, 74.21%, and 89.18%, respectively (Figure 1). Dose-dependent inhibition

of α -amylase enzyme was observed with the both extracts. However, ethanolic extract exhibited more inhibition of α -amylase enzyme (Tables 1 and 2).

a-glucosidase Inhibitory Activity

Aqueous extract of 100, 200, 300, 400, 500 µg doses inhibits

Table 1: IC ₅₀ values for <i>in vitro</i> α -amylase and α -glucosidase inhibition by extracts of <i>C. swietenia</i>						
Sample	Concentration	IC ₅₀	IC ₅₀			
	(µg)	a-amylase	a-glycosidase			
Acarbose (standard)	100	90.8±10.83	75±14.43			
	200					
	300					
	400					
	500					
Aqueous extract	100	446.7±3.63	373.3±4.41			
	200					
	300					
	400					
	500					
Ethanol extract	100	233.3±4.17	236.7±1.67			
	200					
	300					
	400					
	500					

C. swietenia: Chloroxylon swietenia, IC_{50} : Inhibitory concentration, values are expressed as mean+SEM, SEM: Standard error of the mean

Table 2: Correlation coefficient							
Dose		α-Amylas	α-Amylase activity		α -Glycosidase activity		
	Drug	Acarbose	Aqueous extract	Acarbose	Aqueous extract		
100	Acarbose	1	NA	1	NA		
	Aqueous extract	0.728*	1	-0.168	1		
	Ethanolic extract	0.989*	0.819*	-0.408*	-0.832*		
	Acarbose	1	NA	1	NA		
200	Aqueous extract	0.998*	1	0.617*	1		
	Ethanolic extract	0.997*	0.989*	-0.128	0.702*		
300	Acarbose	1	NA	1	NA		
	Aqueous extract	0.967*	1	-0.251	1		
	Ethanolic extract	-0.280	-0.027	1.000	-0.276		
400	Acarbose	1	NA	1	NA		
	Aqueous extract	0.987*	1	0.998*	1		
	Ethanolic extract	-0.089	-0.247	-0.945*	-0.963*		
500	Acarbose	1	NA	1	NA		
	Aqueous extract	-0.940*	1	0.028	1		
	Ethanolic extract	-0.989*	0.981*	-0.776*	0.607*		

*=>P<0.05, NA= Not applicable

the α -glucosidase enzyme by 27.56%, 30.34%, 46.77%, 53.12%, and 60.72%, respectively.

Ethanolic extract of 100, 200, 300, 400, 500 μ g doses inhibits the α -glucosidase enzyme by 34.90%, 49.10%, 58.22%, 61.94%, and 80.94%, respectively.

Acarbose of 100, 200, 300, 400, 500 μ g doses inhibits the α -glucosidase enzyme by 47.96%, 64.89%, 77.36%, 81.27%, and 88.65%, respectively (Figure 2). Dose-dependent % inhibition of α -glucosidase enzyme is observed with the both extracts. However, compare with aqueous extract, ethanolic extract shows more % inhibition of α -glucosidase enzyme (Tables 1 and 2).

DISCUSSION

In diabetes high postprandial blood glucose leads to micro vascular complications include retinopathy, nephropathy, neuropathy, and macrovascular complications refer to increased atherosclerosis-related events such as myocardial infarction and stroke.^[21-23] One of the therapeutic approaches for controlling postprandial hyperglycemia in diabetic



Figure 1: *In vitro* α-amylase inhibitory activity of *Chloroxylon swietenia*





patient is to prevent or decreasing absorption of carbohydrate after food intake. Complex starches, oligosaccharides, and disaccharides must be broken down into monosaccharides by α -amylase and α -glucosidases before they are absorbed in the duodenum and upper jejunum.^[24]

Recent advances in understanding the activity of intestinal enzymes helped in the development of newer pharmacological agents.^[25] α -glucosidase inhibitors reduce intestinal absorption of starch, dextrin, and disaccharides by inhibiting the action of α -glucosidase in the intestinal brush border. Inhibition of this enzyme slows the absorption of carbohydrates from the GI tract and decreases the rate of rise of postprandial glucose (PP hyperglycemia). This delay digestion and breakdown of starch may have beneficial effects on insulin resistance and glycemic index control in people with diabetes.^[26]

Acarbose is α-glucosidase inhibitor which reduces digestion of complex carbohydrates and slows their absorption from the gut.^[27] These drugs also increase the release of the glucoregulatory hormone glucagon-like peptide-1 into the circulation, which may contribute to their glucose-lowering effects.^[28] However, they may causes side effect such as malabsorption, abdominal pain, flatulence, and diarrhea which lead to a high discontinuation rate.^[27] Acarbose and miglitol should not be prescribed in individuals with renal impairment. Acarbose should be used with caution in patients with hepatic diseases because it may cause reversible elevation of hepatic enzymes.^[29]

Experimental results showed that both extracts significantly inhibited the α -glucosidase and α -amylase enzymes. Aqueous extract showed better α -glucosidase inhibitory activity than the α -amylase inhibitory action. Ethanolic extract showed better α -amylase inhibitory activity than the α -glucosidase inhibitory activity than aqueous extract.

Strength and Limitations

There are no previous reports, to the best of our knowledge, about the inhibitory activity of this plant on *in vitro* α -glucosidase and α -amylase. This experiment was conducted only with aqueous and ethanolic leaf extracts. Further studies are required to identify the bioactive compounds that are responsible for the inhibition of α -glucosidase and α -amylase activity.

CONCLUSION

In this study, aqueous and ethanolic leaf extracts of *C. swietenia* showed the *in vitro* antidiabetic activity.

REFERENCES

- 1. Moksha J, Rebecca J. A clinical study of sensory and pain threshold values of upper limb nerves in diabetes mellitus patients. Int J Diabetes Dev Ctries. 2015;35(3):S393-7.
- 2. Basha SK, Kumari VS. *In vitro* antidiabetic activity of *Psidium guajava* leaves extracts. Asian Pac J Trop Dis. 2012;2:S98-100.
- Kumarappan C, Mandal SC. Antidiabetic effect of polyphenol enriched extract of *Ichnocarpus frutescens* on key carbohydrate metabolic enzymes. Int J Diabetes Dev Ctries. 2015;35(4):425-31.
- 4. Pushpanathan P, Srikanth P, Seshadri KG, Selvarajan S, Pitani RS, Kumar TD, et al. Gut microbiota in Type 2 diabetes individuals and correlation with monocyte chemoattractant protein1 and interferon gamma from patients attending a tertiary care centre in Chennai, India. Indian J Endocrinol Metab. 2016;20(4):523-30.
- 5. Kokiwar PR, Guptha S, Durge PM. Prevalance of diabetes in a rural area of central India. Int J Diab Dev Ctries. 2007;27(1):8-10.
- Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of Type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125(3):217-30.
- Ghazanfar H, Rizvi SW, Khurram A, Orooj F, Qaiser I. Impact of insulin pump on quality of life of diabetic patients. Indian J Endocrinol Metab. 2016;20(4):506-11.
- Rastogi A, Shankar S, Mahalingam G. Phytochemical screening, anti-oxidant activity and *in vitro* anti-diabetic activity of aqueous, methanolic, ethanolic and chloroformic extracts of hygrophilaauriculata. Int J Pharm Pharm Sci. 2014;6(5):557-60.
- Patil A, Nirmal S, Pattan S, Tambe V, Tare M. Antidiabetic effect of polyherbal combinations in STZ induced diabetes involve inhibition of α-amylase and α-glucosidase with amelioration of lipid profile. Phytopharmacology. 2012,2(1):46-57.
- Shareef MI, Reddy PJ, Gopinath SM, Dayananda KS, Mandal A, Purushotham KM. *In vitro* α-amylase inhibitory activity of the leaves of *Tinospora cordifolia*. Int J Innov Res Sci Eng Technol. 2014;3(3):10091-6.
- 11. Roy A, Geetha RV. *In vitro* α-amylase and α-glucosidase inhibitory activities of the ethanolic extract of *dioscorea villosa* tubers. Int J Pharm Bio Sci. 2013;4(4):49-54.
- 12. Naini V, Mamidala E. An ethnobotanical study of plants used for the treatment of diabetes in the Warangal district, Andhra Pradesh, India. Biolife. 2013;1(1):24-8.
- Sandhya S, Kumar PS, Vinod KR, Banji D, Kumar K. Plants as potent anti diabetic and wound healing agents - A review. Hygeia J Drugs Med. 2011;3(1):11-9.
- Kumar K, Ganesh M, Baskar S, Srinivasan K, Kanagasabai R, Sambathkumar R, et al. Evaluation of anti-inflammatory activity and toxicity studies of chloroxylon sweitenia in rats. Anc Sci Life. 2006;25(3-4):33-43.
- 15. Harwansh RK, Pareta SK, Patra KC, Jangde R. Screening of *Chloroxylon swietenia* DC root for antibacterial and ant helmintic activities. Pharmacologyonline. 2011;1:544-52.
- 16. Prabakaran R, Arivoli S, Hema A, Kamatchi C. Isolation and characterization of flavonoids from *Chloroxylon swietenia*.

J Chem Pharm Res. 2011;3(3):805-13.

- 17. Deb NK, Dash GK. A review on ethnopharmacolgy, phytochemistry and bioactivity of *Chloroxylon swietenia*. Int J Emerg Trends Pharm Sci. 2013;1(1):11-20.
- Sabitha V, Panneerselvam K, Ramachandran S. *In vitro* alphaglucosidase and alpha-amylase enzyme inhibitory effects in aqueous extracts of *Abelmoscus esculentus* (L.) Moench. Asian Pac J Trop Biomed. 2012;2(2):S162-4.
- Pant G, Sai K, Babasaheb S, Reddy R, Sibi G. *In vitro* α-amylase and α-glucosidase inhibitor activity of *abutilon indicum* leaves. Asian J Pharm Clin Res. 2013;6(5):22-4.
- Vennila V, Pavithra V. *In-vitro* alpha amylase and alpha glucosidase inhibitory activity of various solvent extracts of *Hybanthus enneaspermus* Linn. World J Pharm Pharm Sci. 2015;4(4):1425-37.
- 21. Koda-Kimble MA. Applied Therapeutics: The Clinical Use of Drugs. 9th ed. Ch. 50. USA: Lippincott Williams & Wilkins Publisher; 2009. p. 8.
- Ramachandran A, Snehalatha C, Shetty AS, Nanditha A. Trends in prevalence of diabetes in Asian countries. World J Diabetes. 2012;3(6):110-7.
- Pothireddy S, Chukka S, Shankaraiah P. Evaluation of antidiabetic, antidyslipidemic & hepatoprotective activity of *Homalium zeylanicum* in alloxan induced diabetic rats. Int J Res Dev Pharm Life Sci. 2014;3(3):1004-10.
- Mohamed EA, Siddiqui MJ, Ang LF, Sadikun A, Chan SH, Tan SC, et al. Potent α-glucosidase and a-amylase inhibitory activities of standardized 50% ethanolic extracts and sinensetin

from *Orthosiphon stamineus* Benth as anti-diabetic mechanism. BMC Complement Altern Med. 2012;12:176.

- 25. Narkhede MB, Ajimire PV, Wagh AE, Mohan M, Shivashanmugam AT. *In vitro* antidiabetic activity of *Caesalpina digyna* (R.) Methanol root extract. Asian J Plant Sci Res. 2011;1(2):101-6.
- 26. Uddin N, Hasan MR, Hossain MM, Sarker A, Hasan AH, Islam AF, et al. *In vitro* α-amylase inhibitory activity and *in vivo* hypoglycemic effect of methanol extract of *Citrus macroptera* Montr. Fruit Asian Pac J Trop Biomed. 2014;4(6):473-9.
- Bennett PN, Brown MJ. Clinical Pharmacology. 11th ed. Edinburgh: Churchill Livingstone Elsevier Publisher; 2012. p. 580.
- Brunton LL, Chabner AB, Knollmann CB. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw Hill Publisher; 2011. p. 1264.
- 29. Katzung GB, Masters BS, Trevor JA. Basic & Clinical Pharmacology. 13th ed. New York, NY: McGraw Hill (India) Publisher; 2015. p. 738-9.

How to cite this article: Ramana Murty Kadali SLDV, Das MC, Vijayaraghavan R, Shanmukha I. *In vitro* evaluation of antidiabetic activity of aqueous and ethanolic leaves extracts of *Chloroxylon swietenia*. Natl J Physiol Pharm Pharmacol 2017;7(5):486-490.

Source of Support: Nil, Conflict of Interest: None declared.